

FNIH Biomarkers Consortium Cancer Steering Committee Annual Scientific Symposium

EXECUTIVE SUMMARY

The Biomarkers Consortium Cancer Steering Committee (BC-CSC) Annual Scientific Symposium (formerly the BC-CSC Annual Meeting) brings together experts from academia, pharmaceutical companies, biotechnology companies, not-for-profit organizations, the National Cancer Institute (NCI), the US Food and Drug Administration (FDA), and other federal agencies. Together, they review advances in the field of biomarker and regulatory science relevant to the development of new public-private partnerships for biomarkers.

The Biomarkers Consortium aims to make the 2017 BC-CSC Annual Scientific Symposium the largest, and most inclusive, pre-competitive cancer biomarkers meeting to date with 250+ attendees, speakers, and participants, in person and an additional 250+ via webcast. To achieve this, the FNIH seeks organizational input, expertise and funding support from the cancer research community.

Key Details

Who: The Biomarkers Consortium Cancer Steering Committee (BC-CSC)

What: 2017 BC-CSC Annual Scientific Symposium

When: November 6-7, 2017

Where: Bethesda, MD

This year, the FNIH is offering sponsoring organizations the opportunity to receive additional recognition and benefits at the event.

ABOUT THE BC-CSC ANNUAL SCIENTIFIC SYMPOSIUM

The BC-CSC Annual Scientific Symposium provides an occasion each year to assess and calibrate future directions in biomarker discovery and development through the involvement and interaction of leaders from across the cancer landscape. Led by the FNIH and CSC co-chairs Drs. Gary Kelloff (NCI) and Eric Rubin (Merck), attendees discuss cutting edge science, including many BC-CSC projects. As with all Biomarkers Consortium efforts, these projects are precompetitive, build upon existing infrastructure and produce publicly available results that are shared annually at this event. The Symposium also includes presentations from experts in other critical areas of biomarker science to inform the field of recent developments and help guide BC-CSC decision making, planning and strategy.

Demonstrating the diversity of biomarker science discussed, the BC-CSC Annual Scientific Symposium 2016 agenda showcased projects across the ecosystem of precision medicine and biomarker development, including minimal residual disease, development and regulatory challenges for liquid biopsy, novel imaging improvement, cell-free RNA and DNA research and immuno-oncology. The 2016 meeting also addressed cross-disease relevance by discussing non-cancer biomarker initiatives to assess potential collaboration with researchers in other disease areas. See the 2016 meeting agenda attached.

In 2017, the CSC hopes to actively engage the industry and regulatory science perspective by offering partners the opportunity to design and develop sponsored sessions in collaboration with the co-chairs and by featuring all stakeholders including FDA scientists in panels designed to illuminate the process of regulatory approval for novel biomarkers. The Symposium will also provide more time and opportunities for different stakeholder groups to network and discuss potential collaborations and ideas.

OPPORTUNITIES FOR INVOLVEMENT

The FNIH invites private-sector support and involvement in the BC-CSC Annual Scientific Symposium. Sponsors will receive the following recognition and benefits for their commitment, based on giving levels:

One Exclusive Platinum Sponsorship Opportunity	\$50,000	<ul style="list-style-type: none"> • Recognition with logo on reserved table, meeting room signage, reception signage, introductory slide, and in digital and printed materials • Work with the BC-CSC to develop one panel discussion of your choosing • Ability to display scientific information at Symposium’s dedicated sponsor table • 4 participant invitations
Gold Level Sponsorship Opportunities	\$25,000	<ul style="list-style-type: none"> • Recognition with logo on reserved table, reception signage, introductory slide, and in digital and printed materials • Speaking opportunity in one panel presentation • Ability to display scientific information at Symposium’s dedicated sponsor table • 2 participant invitations
Silver Level Sponsorship Opportunities	\$10,000	<ul style="list-style-type: none"> • Recognition with logo on reserved table, introductory slide, and in digital and printed materials • Ability to display scientific information at Symposium’s dedicated sponsor table • 1 participant invitation
Bronze Level Sponsorship Opportunities	\$2,500	<ul style="list-style-type: none"> • Recognition with name listing on introductory slide and in digital and printed materials • Ability to display scientific information at Symposium’s dedicated sponsor table • 1 participant invitation
Not-for-Profit Sponsorship Opportunities	\$500	<ul style="list-style-type: none"> • Recognition with name listing on introductory slide and in digital and printed materials • Ability to display scientific information at Symposium’s dedicated sponsor table • 1 participant invitation

CONCLUSION

The FNIH aims to secure funding commitments for the Symposium by August 2017. This will ensure sponsors are involved in Symposium planning and development. If you are interested in sponsoring this event or need more information regarding the BC-CSC Symposium, please contact:

Meredith Donnelly Senior Development Officer (301) 443-1744 mdonnelly@fnih.org	Dinetta Parrott Development Officer (301) 443-2103 dparrott@fnih.org	Eric Barese Development Officer (301) 435-4493 ebarese@fnih.org	Julie Wolf-Rodda Director of Development (301) 402-6027 jwolf-rodda@fnih.org
---	--	--	---

If you have questions about the Biomarkers Consortium or Cancer Steering Committee, please contact:

Stacey Adam Scientific Program Manager, Cancer (301) 345-8364 sadam@fnih.org	Dana E. Connors Scientific Project Manager, Cancer (301) 435-2613 dconnors@fnih.org
---	---

The Biomarkers Consortium (BC) at the Foundation for the National Institutes of Health (FNIH) is the preeminent public-private partnership in advancing biomarkers that accelerate therapeutic development and improve clinical care. It has representation from NIH, FDA, PhRMA, CMS, and over 30 companies and not-for-profit organizations. Currently the BC is focused on developing projects in cancer, immunity and inflammation, metabolic disorders and neuroscience.